PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.
94.32
OCF/share exceeds 1.5x the Medical - Pharmaceuticals median of 0.05. Joel Greenblatt would see if this strong cash generation is sustainable.
56.82
FCF/share of 56.82 while Medical - Pharmaceuticals median is zero. Walter Schloss would see if small leftover cash can become a big advantage.
39.76%
Capex/OCF ratio of 39.76% while the Medical - Pharmaceuticals median is zero. Walter Schloss would confirm if minimal reinvestment is enough for advantage.
1.37
Ratio near Medical - Pharmaceuticals median of 1.41. Charlie Munger might see standard alignment across the industry.
6.28%
OCF-to-sales ratio exceeding 1.5x Medical - Pharmaceuticals median of 0.89%. Joel Greenblatt would see a standout ability to convert sales to cash.